Malaysian glove maker Harps weighs US$500m IPO
[KUALA LUMPUR] Malaysian glove maker Harps Holdings is weighing an initial public offering (IPO) in Kuala Lumpur to raise about US$500 million, according to people with knowledge of the matter.
The company is working with advisers on the potential first-time share sale, which could take place as soon as the first half of next year, the people said. Harps is seeking a listing on the back of strong demand for gloves during the coronavirus pandemic, said the people, who asked not to be named as the information is private.
Malaysian stocks have rallied more than 30 per cent from their March low as the Covid-19 outbreak boosted demand for medical gloves and hence shares of their manufacturers, several of which are listed in the country. Top Glove, the world's biggest glove maker, rose more than six-fold this year, while Supermax surged more than 1,500 per cent.
Harps bought lightweight nitrile examination glove maker Central Medicare in 2015, according to the unit's website. Central Medicare operates 24 double-former production lines that contribute to a total monthly output of 590 million units of gloves.
Political and economic uncertainties have slowed the IPO activity in Malaysia. Companies have raised US$70.7 million through first-time share sales so far this year, the lowest in more than a decade, according to data compiled by Bloomberg.
Deliberations on the potential IPO are at an early stage and details including size and timeline could still change, the people said. A representative for Harps Holdings didn't immediately respond to requests for comment.
GET BT IN YOUR INBOX DAILY
Start and end each day with the latest news stories and analyses delivered straight to your inbox.
BLOOMBERG
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Billionaire Geiger is said to near US$7 billion L’Occitane buyout
HCA beats first-quarter profit estimates on higher patient admissions
US FDA approves Pfizer’s gene therapy for rare bleeding disorder
EU toughens rules on Chinese fashion retailer Shein
Best World under fire from shareholders at AGM over dividends, director salaries
‘Extreme’ climate blamed for world’s worst wine harvest in 62 years